EGFR antibody [29.1]

GeneTex

EGFR antibody [29.1]

9

WB: 1:3,000. ELISA: 1:10,000. IHC: 1:50. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

ImmunoPrecipitation, Western Blot, ELISA, ImmunoHistoChemistry

Research Use Only

Monoclonal

29.1

Unconjugated

EGFR

epidermal growth factor receptor

avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; epidermal growth factor receptor; epidermal growth factor receptor tyrosine kinase domain; ERBB; ERBB1; erb-b2 receptor tyrosine kinase 1; ERRP; HER1; mENA; NISBD2; PIG61; proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1

Mouse

IgG1

Epidermal growth factor receptor

The receptor for Epidermal Growth Factor is an integral cell membrane protein of 170 kDa, which spans the membranes of a wide range of normal and malignant epithelial cells. It is a tyrosine-specific protein kinase with the capacity to phosphorylate tyrosine residues located near its carboxy-terminus. EGF-R has anextracellular region which binds EGF and consequently mediates the initial response of cells to EGF and an intra- cellular region which posseses the tyrosine kinase activity. As a result of EGF binding to its specific receptor, there is increased DNA synthesis as well as other events such as cell proliferation, differentiationand repair of damaged epithelial tissue. The EGF-R has a half-life of approximately 10 hours in human fibroblasts, but in the presence of EGF this value is reduced to about 1 hour. A close similarity has been found between the sequence of the v-erb-B oncogene and the cytoplasmic and transmembrane part of the EGF-R (truncated EGF-R). It is hypothesized that an inappropriate activation of the human erb-B gene either by truncation or overexpression plays a role in the development of the malignancy. This hypothesis is supported by studies which have shown an increased number of EGF-R in various malignant tumors. High levels of EGF-R have been identified in sarcomas, gliomas, gynecological, breast, bladder and lungtumors.

-20°C or -80°C,2°C to 8°C

12352203